Rho kinase inhibitor and beta‐blocker vs beta‐blocker
Difference in mean IOP from baseline at < 6 months · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
- Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 208 participantsModerate